Labiotech.eu

nanoparticles cancer thermotherapy UK2 1

News and Trends 25 Oct 2017

British Researchers Develop Clever Nanoparticles to Kill Cancer Cells

The University of Surrey has developed nanoparticles that heat up to kill cancer cells, but can then be controlled to protect healthy tissue. Research from the University of Surrey, published in Nanoscale, has been put forward as a new form of thermotherapy. Although it has been available for a long time, thermotherapy’s use is limited by […]

October 25, 2017 - 3 minutesmins - By Alex Dale

News and Trends 25 Oct 2017

The UK Recommends the use of GSK’s €594,000 Gene Therapy

Amidst uncertainty about the commercial future of expensive gene therapies, the UK’s NICE has declared GSK’s Strimvelis offers “value for money.” Approved by the EMA last year, Strimvelis is one of the most expensive drugs on the market. Although GSK is offering a money-back guarantee and payment through instalments, the price of the gene therapy, […]

October 25, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 25 Oct 2017

What Could RNA Therapies Do for the Treatment of CNS Disorders?

Evelyn chatted with Thomas de Vlaam to find out what his company, Amylon, is working on and how it hopes to change the field fighting CNS disorders. De Vlaam came up with AT-010, a drug candidate for the treatment of Katwijk‘s disease, during his time at ProQR. When it became clear that he had something […]

October 25, 2017 - 3 minutesmins - By Alex Dale

News and Trends 24 Oct 2017

Update: GSK’s Shingles Vaccines Impresses FDA Panel who Push for its Approval

Update (24/10/2017): Shingrix has been approved by the FDA and will cost $280 (€238) for the required two shots, which should be covered by most insurance plans. Originally published on 13/9/2017 An FDA panel voted 11-0 to support the approval of GSK’s new shingles vaccine based on “impressive” efficacy and safety results in a Phase III […]

October 24, 2017 - 3 minutesmins - By Alex Dale

News and Trends 24 Oct 2017

British Scientists Prove that it Takes Very Few Mutations to Cause Cancer

Researchers in the UK have analyzed over 7,500 tumors and estimate that a very low number of mutations is needed for cancer to develop. Researchers coming out of the prestigious Sanger Institute in Cambridge, UK has estimated that as few as 1 to 10 mutations are required to cause cancer. The study, published in Cell, was […]

October 24, 2017 - 2 minutesmins - By Alex Dale

News and Trends 24 Oct 2017

French Biotech‘s Bacterial Product is Ready to Enter the Anti-Aging Skincare Market

Montpellier-based Deinove has developed a bacterial anti-aging skincare product, which has shown its safety and healing capacity in studies so far. Deinove specializes in high-value compounds from rare bacteria, in particular, the Deinococcus genus. It has announced that it will launch its first cosmetic product into the anti-aging skincare market in 2018, which is based on a […]

October 24, 2017 - 2 minutesmins - By Alex Dale

In Depth 24 Oct 2017

Where to Find the Money to Get Your Biotech Startup Up with the Big Boys

What do you need to kickstart your own biotech company? A great idea, of course. Industry knowledge, a plus. Money… This could be tricky. Breaking into the biotech industry is one of the most expensive decisions that you can make. First, you need ground-breaking science that has what it takes to change its respective field, […]

October 24, 2017 - 8 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation

TiGenix’s candidate for a nasty Crohn’s disease complication received orphan drug designation after agreeing on a global Phase III trial. TiGenix exploits the anti-inflammatory properties of donor-derived stem cells to treat diseases. One of its candidates, Cx601, is targeted at a complication of Crohn’s disease – a nasty inflammatory condition affecting the intestine. Cx601 met efficacy and safety […]

October 23, 2017 - 2 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

Transgene‘s Hepatitis B Vaccine Does the Business at Phase I

The French biotech‘s hepatitis B vaccine has demonstrated good efficacy and safety, suggesting it could provide effective protection from the virus. Biotech veteran, Transgene, specializes in viral-based immunotherapies for cancers and infectious diseases. One of its targets, hepatitis B, is a potentially fatal liver infection caused by the hepatitis B virus (HBV). Today, it has […]

October 23, 2017 - 2 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

Swiss Biotech Rakes in $200M to Accelerate Antibody-based Cancer Treatments

ADC Therapeutics has received massive private funding to progress two of its lead candidates for cancer through clinical trials. ADC Therapeutics, based in Lausanne, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for the treatment of cancer. The technology uses the specificity of antibodies to deliver a therapeutic agent to target cells only. The biotech has […]

October 23, 2017 - 3 minutesmins - By Alex Dale

News and Trends 23 Oct 2017

Peanut Allergy Trial Fails but French Biotech Keeps Pushing for Approval

DBV Technologies plans to go ahead with its peanut allergy treatment despite its failure to meet a primary endpoint in Phase III. Last Friday, DBV Technologies released the results of a Phase III trial that was key to the approval of a treatment to reduce peanut allergy in children. After 12 months, 35% of children […]

October 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Oct 2017

A Peptide Reduces Bleeding in Surgery in Phase II Trials

Ergomed has announced positive results in Phase II with PeproStat, a peptide solution to stop bleeding during surgery faster. In a Phase II study that recruited 169 patients across 16 European hospitals, London-based Ergomed has demonstrated that itspipeline’s lead candidate, PeproStat, can reduce the time to achieve hemostasis, that is, for the bleeding to stop, […]

October 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

British Researchers Develop Clever Nanoparticles to Kill Cancer Cells

The UK Recommends the use of GSK’s €594,000 Gene Therapy

What Could RNA Therapies Do for the Treatment of CNS Disorders?

Update: GSK’s Shingles Vaccines Impresses FDA Panel who Push for its Approval

British Scientists Prove that it Takes Very Few Mutations to Cause Cancer

French Biotech‘s Bacterial Product is Ready to Enter the Anti-Aging Skincare Market

Where to Find the Money to Get Your Biotech Startup Up with the Big Boys

FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation

Transgene‘s Hepatitis B Vaccine Does the Business at Phase I

Swiss Biotech Rakes in $200M to Accelerate Antibody-based Cancer Treatments

Peanut Allergy Trial Fails but French Biotech Keeps Pushing for Approval

A Peptide Reduces Bleeding in Surgery in Phase II Trials

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!